On February 17, Truist increased Cigna's price target to $350 from $320 and maintained a Buy rating after updating its financial model based on Q4 results and the company’s initial 2026 outlook. Cigna delivered adjusted full-year revenue of $275 billion, an 11% year-over-year increase, while adjusted earnings per share reached $29.84, up 9% from the prior year, reflecting steady underlying growth. Management highlighted several strategic moves, including boosting investment in Shields Health Solutions, completing the divestiture of its Medicare business, settling FTC pharmacy benefit issues with a $7 billion customer relief agreement over 10 years, and launching a rebate-free pharmacy benefit model to enhance long-term growth visibility.